An im bal ance in the serotonergic neu rotrans mit ter sys tem may un der lie as pects of the pa thol ogy ob served in au tis tic patients (1) . Risperidone, an atyp i cal antipsychotic that is both a se ro to nin and do pa mine an tag o nist, has been shown to treat adults with au tism ef fec tively (2) . Studies have shown that risperidone also im proves symp toms in sev eral psy chi atric dis or ders of older chil dren and ad oles cents (3) (4) (5) . In this let ter, we de scribe its use for treat ing chil dren with au tism. Our sam ple con sisted of 9 sub jects with a DSM-IV di ag no sis of au tis tic dis or der (7 males and 2 fe males; me dian age 7.1 yrs, range 3.4 to 13.4 yrs). Screening pro ce dures in cluded med i cal his tory, phys i cal and neu ro log i cal ex am i na tions, com plete blood count, elec tro lytes, glucose, se rum urea ni tro gen, creatinine, liver func tion, uri nal y sis, ECG, EEG, and au di tory evoked po ten tials. Pa tients were drug-free for at least 4 weeks before the be gin ning of the trial. No other psy cho ac tive med i ca tion was given during the study.
The sub jects un der went a 12-month trial. Risperidone was started at 0.5 mg daily and ti trated up ward to a max i mum of 3 mg daily.
Be hav ioural rat ings were car ried out at base line and at fixed in ter vals (3, 6 , and 12 months). The fol low ing in stru ments were em ployed: Clin i cal Global Im pression (CGI) (6), Be hav ioural Sum marized Eval u a tion Scale (BSE) (7) , and Vineland So cial Ma tu rity Scale (VSMS) (8) .
Most of the screen ing tests, in clud ing com plete blood count, liver func tion, elec tro lytes, glu cose, se rum urea ni trogen, creatinine, uri nal y sis, and EEG, were also per formed 3 times dur ing the study (at 3, 6, and 12 months). Blood pres sure was mon i tored dur ing the first days of the trial. Side ef fects were eval uated us ing the Extrapyramidal Symptoms Rat ing Scale (ESRS) (9) .
Three pa tients were with drawn from the study due to fam ily non com pli ance, and 6 sub jects com pleted the whole trial.
All par ents re ported some be hav ioural im prove ment, such as in creased awareness and so cial in ter ac tion, as well as decreased self-abuse, ir ri ta bil ity, hy per ac tiv ity, and sleep dis tur bance.
Five of the 6 risperidone-treated pa tients were cat e go rized as re spond ers on the ba sis of the CGI Scale. The Wilcoxon signed-rank test showed that the decrease in the to tal BSE score be tween base line and month 12 was sta tis ti cally sig nif i cant (P = 0.03). No sig nif i cant changes were noted us ing the VSMS.
Un to ward ef fects in cluded mild se dation (2 cases) and weight gain (1 case). One of the pa tients ex pe ri enced an ep ilep tic sei zure 6 months af ter start ing risperidone ther apy. Liver func tion tests, EEG, and other lab o ra tory stud ies re mained within nor mal lim its. Blood pres sure did not vary from nor mal val ues.
Our study showed that risperidone was able to re duce self-abuse, ag gres sion, and hy per ac tiv ity in au tis tic chil dren. The ob vi ous fac tors ham per ing its gener al iza tion in clude the small num ber of pa tients, the unblind na ture, and the lack of con trol groups. Con trolled re search is needed to fur ther eval u ate the ef fi cacy of risperidone in treat ing au tism. I re port the case of a 48-year-old male phy si cian who pre sented with a ma jor de pres sive ep i sode (MDE). He had suffered with sea sonal af fec tive dis or der (SAD) for sev eral years. He de scribed him self as al ways hav ing been ob sessional and perfectionistic.
Ini tially, he had re sponded pos i tively to citalopram at a dos age of 20 mg daily, although he had ex pe ri enced sig nif i cant sex ual side ef fects and a with drawal syndrome when he dis con tin ued it. There is a pos i tive fam ily his tory of de pres sive ill ness in his mother postmenopause, requir ing hos pi tal iza tion and re spon sive to med i ca tion man age ment. His 18-year-old son also pre sented with depres sive ill ness at the same time as the fa ther and ini tially re sponded pos i tively to bupropion (Wellbutrin).
Ma jor de pres sion was ev i dent in clin i cal in ter view, with self-re port, Beck Depres sion In ven tory (BDI), and the Hospi tal Anx i ety and De pres sion and (HAD) Scale show ing mod er ately severe de pres sion with as so ci ated anx i ety. The pa tient was tak ing beta blockers for es sen tial hy per ten sion, which was well con trolled. He had self-med i cated with nefazodone at doses up to 200 mg daily, with lit tle ev i dent ben e fit apart from improved sleep pat tern. When he was next as sessed, the de pres sive af fect was more sig nif i cant. Bupropion SR was added at a dos age of 150 mg daily, with some clonazepam as needed for break through panic. Clin i cal im prove ment in de pres sion was ev i dent within 8 weeks, as re ported by the pa tient and his fam ily and as ob served in in ter view.
At 12 weeks, the pa tient com plained of tremor, nau sea, micrographia, and shuffling gait. These symp toms had emerged within 10 weeks of the ini tial bupropion pre scrip tion. He dis con tin ued the bupropion and the symp toms re solved over 10 days. The de pres sion wors ened, how ever, as the extrapyramidal symptoms re solved. At tempts at re in tro ducing the bupropion at lower doses were un suc cess ful, and the pa tient now contin ues on nefazodone plus fluoxetine, with the ad di tion of light treat ment, with sig nif i cant clin i cal im prove ment.
A re view of the lit er a ture from the Drug In for ma tion Ser vice showed 2 case reports of re vers ible orofacial dyskinesia af fect ing the eyes and tongue in a 70-year-old woman re ceiv ing bupropion at doses from 75 to 225 mg daily. Other symp toms in cluded hand tremor, nau sea, and diz zi ness. Af ter discon tinu a tion, the dyskinesia re ceded, and other side ef fects dis ap peared.
Two other ge ri at ric pa tients (aged 85 and 72 years) were treated with bupropion for ma jor de pres sion and expe ri enced a "fall ing back ward" re ac tion. Max i mum dos ages in each pa tient were up to 400 mg and 350 mg daily, re spectively. Nei ther pa tient had a his tory of orthostatic hypotension or ver tigo. Both did man i fest other symp toms con sis tent with parkinsonian syn drome (for ex ample, akinesia and shuf fling gait). Af ter bupropion was dis con tin ued, these adverse ef fects re solved within 1 to 2 weeks.
The lit er a ture sug gests that at ther a peutic doses bupropion ex hib its do pamine-ag o nist ef fects, and at high doses it may have a do pa mine-an tag o nist ef fect. The man u fac turer does have some case re ports pre-and postmarketing of parkinsonian-type side ef fects, but no causal re la tion has yet been es tab lished.
There was 1 re port of a 53-year-old patient who had a dystonic re ac tion with nefazadone 2 hours af ter the first dose. This pa tient's chief com plaint was lip smack ing, with hand and arm ges tur ing. The symp toms re solved within 1 hour in re sponse to diphenhydramine and benztropine. The Drug In for ma tion search did not yield any ki netic in ter actions be tween nefazadone and bupropion that might have re sulted in a fur ther in crease in bupropion se rum levels. There was no fam ily his tory of neuro log i cal dis or der or Par kin son's dis ease in this pa tient.
